Voyager Therapeutics to Host R&D Day and Webcast on April 29, 2016
CAMBRIDGE, Mass., April 14, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc.(NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that the Company will host an R&D Day on Friday, April 29, 2016, from 8:30 a.m. – 11:00 a.m. ET in New York City.
During the R&D day, presentations by members of Voyager’s management team and guest speakers will include:
- Unmet Medical Needs in Parkinson’s Disease and Potential Treatment Using Gene Therapy
Andrew S. Feigin, M.D.
Director, Experimental Therapeutics for Movement Disorders, Feinstein Institute
Director, Huntington’s Disease Society of America Center of Excellence, North Shore University Hospital
- Overview of VY-AADC01 for Parkinson’s Disease
Bernard Ravina, M.D.
Vice President, Clinical Development, Voyager Therapeutics
- Role of Superoxide Dismutase 1 in ALS and the Potential for Targeted Treatment Using Gene Therapy
Robert H. Brown, D.Phil., M.D.
Professor and Chair of Neurology, University of Massachusetts Medical School
Director, Day Neuromuscular Research Laboratory, University of Massachusetts Medical School
- Overview of VY-SOD101 for a Monogenic Form of ALS
Dinah Sah, Ph.D.
Senior Vice President, Neuroscience, Voyager Therapeutics
- New Opportunities in CNS Gene Therapy
Steve Paul, M.D.
President and CEO, Voyager Therapeutics
A live audio webcast of the R&D Day and replay will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. A replay of the presentation will be posted on the Voyager website approximately one hour after the live event and will be available for 30 days following the presentation.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.